Chinese Hamster Ovary (i.e., Cho) Patents (Class 435/358)
  • Patent number: 10104881
    Abstract: The present invention relates to a composition including plant-derived recombinant human serum albumin, lipids, and plant protein hydrolysates as active ingredients for cryopreservation of stem cells or primary cells, and use thereof, more particularly, to a composition including plant-derived recombinant human serum albumin, lipids, and plant protein hydrolysates as active ingredients for cryopreservation of stem cells or primary cells, in which the albumin, lipids, and plant protein hydrolysates are present in sufficient quantities to reduce cell death caused by freezing while maintaining animal-free and xeno-free conditions during long-term preservation of stem cells or primary cells; and to a method for cryopreservation of stem cells or primary cells using the composition.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: October 23, 2018
    Assignee: CEFO CO., LTD.
    Inventors: Sunray Lee, Jin Yup Lee, Hyun Jung Mo, Hyun-Sook Park
  • Patent number: 10000757
    Abstract: A gene vector comprising a miRNA sequence target.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: June 19, 2018
    Assignees: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE TELETHON
    Inventors: Luigi Naldini, Brian Brown
  • Patent number: 9932605
    Abstract: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: April 3, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Robert Babb, James P. Fandl
  • Patent number: 9738724
    Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: August 22, 2017
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
  • Patent number: 9611285
    Abstract: The present invention relates to nucleic acid and amino acid sequences from Escherichia coli serogroup O126, coding for/representing a novel alpha-1,2-fucosyltransferase. The invention also provides uses and methods for using the alpha-1,2-fucosyltransferase to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular oligosaccharides found in human milk, such as 2?-fucosyllactose.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 4, 2017
    Assignee: Jennewein Biotechnologie GmbH
    Inventors: Julia Parkot, Eric Huefner, Stefan Jennewein, Lothar Elling, Leonie Engels
  • Patent number: 9556438
    Abstract: A gene vector comprising a miRNA sequence target.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: January 31, 2017
    Assignees: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR, FONDAZIONE TELETHON
    Inventors: Luigi Naldini, Brian Brown
  • Patent number: 9228168
    Abstract: The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: January 5, 2016
    Assignee: Amgen Inc.
    Inventors: Arvia Eleanor Morris, Aurora Villegas Viaje, Erika Pineda
  • Patent number: 9222106
    Abstract: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: December 29, 2015
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Robert Babb, James P. Fandl
  • Publication number: 20150140607
    Abstract: The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a CHO cell line. More specifically, the invention pertains to a combination of (i) a DNA vector suitable for production of a recombinant protein, wherein said vector comprises a sequence coding for a glutamine synthetase, and (ii) a Chinese Hamster Ovary (CHO) cell line, wherein said GS comprises a sequence at least 94.5% identical to the sequence of SEQ ID NO: 1 or to the sequence of SEQ ID NO: 2.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SANOFI
    Inventors: Catherine Devaud, Bruno Dumas, Nabil Lounis
  • Publication number: 20150140591
    Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 21, 2015
    Inventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
  • Patent number: 9034649
    Abstract: This invention relates to a method for producing a protein of interest, comprising introducing a protein expression vector which comprises a gene fragment a gene fragment comprising a DNA encoding a protein of interest and a selectable marker gene and transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell to obtain a mammalian cell capable of expressing the protein of interest; and suspension-culturing the mammalian cell; and a suspension mammalian cell capable of expressing the protein of interest.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: May 19, 2015
    Assignees: Inter-University Research Institute Corporation Research Organization of Information and Systems, KYOWA HAKKO KIRIN CO., LTD
    Inventors: Koichi Kawakami, Keina Yamaguchi, Risa Ogawa, Masayoshi Tsukahara
  • Publication number: 20150132845
    Abstract: Devices, systems, and methods for continuous cell culture and other reactions are generally described. In some embodiments, chambers (e.g., cell growth chambers) including at least a portion of a wall formed of a flexible member are provided. A retaining structure can be incorporated outside and proximate to the chamber such that when liquid is added to the chamber, the flexible member is consistently and predictably deformed, and a consistent volume of liquid is added. The flexible member can be formed of, in some embodiments, a gas-permeable medium. In some embodiments, reaction chambers can be arranged in a fluidic loop, and a bypass channel can be used to introduce and/or extract fluid from the loop without affecting loop operation.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 14, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Rajeev Jagga Ram, Kevin Shao-Kwan Lee
  • Publication number: 20150133379
    Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 14, 2015
    Inventors: Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
  • Publication number: 20150132277
    Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20150133317
    Abstract: Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 14, 2015
    Applicants: Department of Veterans Affairs, The Board of Trustees of the Leland Stanford Junior University
    Inventors: William H. Robinson, Yann Chong Tan, Jeremy Sokolove
  • Publication number: 20150125893
    Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Wolf B. Frommer, Cheng-Hsun Ho
  • Publication number: 20150118754
    Abstract: The present invention related to a polynucleotide sequence and an expression vector comprising at least one gene encoding a stress resistance protein, at least one gene encoding a selection marker, at least one gene encoding an expression protein, at least one matrix attachment region and a transcription terminator, all of which are operably connected to each other. The present invention further relates to a host cell comprising the expression vector. The present invention also relates a method of producing a cell line.
    Type: Application
    Filed: April 1, 2013
    Publication date: April 30, 2015
    Applicant: BioGenomics Limited
    Inventors: Archana Rajesh Krishnan, Sanjay Madhukar Sonar, Damodar Krishnabahadur Thappa
  • Publication number: 20150111222
    Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
    Type: Application
    Filed: August 8, 2012
    Publication date: April 23, 2015
    Applicant: HOWARD hUGHES MEDICAL INSTITUTE
    Inventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
  • Publication number: 20150111233
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Satoshi INOUYE, Junichi SATO
  • Publication number: 20150104867
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: May 2, 2014
    Publication date: April 16, 2015
    Applicants: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Publication number: 20150104450
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Publication number: 20150099705
    Abstract: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Mack FLINSPACH, Alan Wickenden, Ross Fellows, Robert Neff, Yi Liu, Rebecca Hagan, Qinghao Xu
  • Publication number: 20150094271
    Abstract: A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventors: Jung-Hoon Lee, Eunji Kang, Hye Yoon Kang, Dongkyu Shin, Jae Il Lee, Jieun Han, Jung Min Lee
  • Publication number: 20150094450
    Abstract: The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases.
    Type: Application
    Filed: February 27, 2013
    Publication date: April 2, 2015
    Applicants: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), KOREA BASIC SCIENCE INSTITUTE
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Jung Min Choi, Eun-Kyeong Jo, Chul-Su Yang, Hae-Kap Cheong, Hyun Jung Kim
  • Publication number: 20150087596
    Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
  • Publication number: 20150087604
    Abstract: The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity.
    Type: Application
    Filed: April 16, 2012
    Publication date: March 26, 2015
    Inventors: Xiaodong Zhang, Lihong Ye
  • Patent number: 8986957
    Abstract: A cell culture medium with high content of choline chloride is provided. The cell culture media further comprise only moderate amounts of amino acids, in particular the amount of glutamine in the cell culture media is limited. The cell culture media can be used for large scale production of polypeptides using cell cultures. The cell culture media with high content of choline chloride are particularly suitable for fed-batch cell culture whereby cell viabilities stay at a higher level for a longer time and high polypeptide titers although limited amounts of amino acids are used.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: March 24, 2015
    Assignee: Novartis AG
    Inventors: Wolfgang Ernst Gustav Budach, Helene C. Chassin, Kerstin Dorsch
  • Publication number: 20150079127
    Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 19, 2015
    Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jos Kleuskens, Andreas Walter Claudius Rohwer
  • Publication number: 20150079634
    Abstract: The present invention is related to a method to reduce peptide amidation activity in a given cell line, cell lines with reduced peptide amidation activity, and uses thereof.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 19, 2015
    Inventors: Mihaela Skulj, Dominik Gaser
  • Publication number: 20150079659
    Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.
    Type: Application
    Filed: May 22, 2014
    Publication date: March 19, 2015
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Stephen GORFIEN, Richard FIKE, GLENN GODWIN, JOYCE WOLANSKE, David EPSTEIN, Dale GRUBER, Don MCCLURE, Paul PRICE
  • Patent number: 8980579
    Abstract: Provided herein are methods for stable integration and/or expression of one or more recombinant polynucleotides in a host cell. The recombinant polynucleotides are typically integrated into the host genome at some native chromosomal integration sites. The integration can be mediated by homologous recombination or by using a hybrid recombinase targeting the specific chromosomal locations. The native chromosomal integration sites in the host cells, which support stable integration and strong transcription activities of foreign genes, are present within or adjacent to specific genes in the CHO genome, the ankyrin 2 gene (Ank2), cleavage and polydenylation specific factor 4 gene (Cpsf4), C-Mos gene, and Nephrocystin-1/Mal gene. Also provided are methods and nucleic acid molecules for inserting site-specific recombination sequences (chromosomal landing pads) into these specific chromosomal locations, engineered host cells containing chromosomal landing pads, methods and compositions (e.g., kits) therefore.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: March 17, 2015
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Wei Zhou, Bruce Cunningham, Gerald M. Edelman
  • Patent number: 8980583
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 17, 2015
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Publication number: 20150072368
    Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.
    Type: Application
    Filed: February 8, 2013
    Publication date: March 12, 2015
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, François Coutard
  • Publication number: 20150072415
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Application
    Filed: March 31, 2014
    Publication date: March 12, 2015
    Applicant: Baxter Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Publication number: 20150072383
    Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents. The present disclosure provides engineered polypeptides having transaminase activity, polynucleotides encoding the polypeptides, methods of the making the polypeptides, and methods of using the polypeptides for the biocatalytic conversion of ketone substrates to amine products. The present enzymes have been engineered to have one or more residue differences as compared to the amino acid sequence of the naturally occurring transaminase of Vibrio fluvialis. In particular, the transaminases of the present disclosure have been engineered for efficient formation of chiral tryptamine derivatives from its corresponding prochiral ketone substrates.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 12, 2015
    Inventors: Jovana Nazor, Derek Smith, Michael Crowe, Shiwei Song, Steven J. Collier
  • Publication number: 20150072353
    Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.
    Type: Application
    Filed: August 21, 2014
    Publication date: March 12, 2015
    Inventors: Jenny Jie Yang, Shen Tang
  • Publication number: 20150071883
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 12, 2015
    Inventor: Peter Cameron Colosi
  • Publication number: 20150064201
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 5, 2015
    Inventors: GARY PETER BEMBRIDGE, CHUN-WA CHUNG, SUSANNAH KAREN FORD, IAN KIRBY, RUTH MCADAM, MARIA FEENEY
  • Publication number: 20150064183
    Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 5, 2015
    Inventors: Jonathan LeBowitz, Stephen M. Beverley
  • Publication number: 20150064185
    Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 5, 2015
    Inventors: Lucy J. HOLT, Ian M. Tomlinson
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Publication number: 20150056271
    Abstract: Factor VIII variants and methods of use thereof are disclosed.
    Type: Application
    Filed: August 25, 2014
    Publication date: February 26, 2015
    Inventors: Valder Arruda, Rodney Camire, Nicholas Iacobelli
  • Publication number: 20150056199
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 8962290
    Abstract: A method of increasing animal cell growth and monoclonal antibody production in an animal cell or cell culture includes the use of ultrasound at a frequency greater than about 1 MHz.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: February 24, 2015
    Assignee: Intelligentnano Inc.
    Inventors: Jie Chen, James Xing, Woon T. Ang, Hilal Gul
  • Publication number: 20150050273
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 19, 2015
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Patent number: 8956830
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Publication number: 20150044769
    Abstract: A cell of a cell line adapted to a protein-free and lipid-free medium, which is derived from CHO cells, can be stably used for production of recombinant proteins and can proliferate in a suspended state in a protein-free and lipid-free medium containing no exogenous growth factors. A method for adapting CHO cells by using a protein-free and lipid-free medium and a medium used for the method.
    Type: Application
    Filed: February 21, 2014
    Publication date: February 12, 2015
    Applicant: Kyokuto Pharmaceutical Industrial Co., Ltd.
    Inventor: Tetsuji Sasaki
  • Publication number: 20150044753
    Abstract: The present invention relates to a vector comprising a polynucleotide encoding a modified glutamine synthetase (GS), and a method for preparing a target protein employing the same. More particularly, the present invention relates to a modified GS having an increased sensitivity to a glutamine synthetase (GS) inhibitor, a polynucleotide encoding the modified GS, a vector comprising the polynucleotide, a transformant comprising the vector, and a method for preparing a target protein using the transformant.
    Type: Application
    Filed: March 5, 2013
    Publication date: February 12, 2015
    Inventors: Hyun Sook Jang, Dong Heon Lee, Sun Kyu Kim, Yong Ho Ahn, Sang Kyung Park
  • Publication number: 20150044768
    Abstract: The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consistng of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: FANG JIN, RICHARD N. HARKINS, MAXINE BAUZON, TERRY HERMISTON